Product Code: iDATA_GLOB25_MC_BGS
The global bone graft substitute (BGS) market was valued at approximately $2.83 billion in 2024 and is expected to grow at a CAGR of 4.1%, reaching approximately $3.75 billion by 2031. The market includes various types of bone graft substitutes used in orthopedic, trauma, and reconstructive surgeries.
The BGS market is segmented into:
- Allograft BGS
- Demineralized Bone Matrix (DBM) Allograft BGS
- Synthetic BGS
The market is further categorized based on indication type:
- Spine (Cervical, Thoracolumbar)
- Trauma (Non-union, Fresh Fracture)
- Large Joint Reconstruction (Hip, Knee)
- Craniomaxillofacial
- Oncology
- Foot Bone Reconstructions
Market Insights
- Unit Sales & Average Selling Prices
- Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2031
- Recent Mergers & Acquisitions
- Competitive Landscape
- Company Profiles & Product Portfolios
Market Trends
- The COVID-19 pandemic caused a decline in BGS sales due to postponed elective surgeries. However, the market recovered strongly by 2022 and resumed steady growth.
- Minimally invasive techniques are driving the adoption of synthetic and DBM-based grafts over traditional bone grafting procedures.
- Rising orthopedic procedures due to an aging population and increasing trauma-related injuries are fueling market growth.
- Technological advancements in bioengineered bone grafts are increasing graft efficiency and patient outcomes.
Market Share Insights
Top Competitors in the Global Bone Graft Substitute Market (2024):
1 Medtronic
* Market leader due to a dominant share in the DBM and synthetic BGS segments.
* Grafton(R) - The first fiber-based DBM allograft BGS and one of the most widely used.
* MASTERGRAFT(R) - Synthetic BGS product line available in granules, moldable putty, flexible strip, and matrix EXT.
2 Stryker
* Second-largest competitor in the market.
* Offers multiple BGS products including Vitoss(TM), ALLOMATRIX(R), FUSIONFLEX(R), and PRO-STIM(R).
3 DePuy Synthes (Johnson & Johnson)
* Third-largest competitor in the BGS market.
* Competes with its DBX(R) DBM product line and chronOS(R) synthetic BGS.
Global Research Scope
* North America: United States, Canada
* Latin America: Brazil, Mexico, Chile, Colombia
* Western Europe: Germany, France, Italy, Spain, United Kingdom
* Central & Eastern Europe: Poland, Russia, Turkey
* Middle East: Saudi Arabia, UAE, Israel
* Asia Pacific: China, Japan, India, South Korea
* Africa: South Africa, Egypt, Nigeria
- Base Year: 2024
- Forecast Period: 2025-2031
- Historical Data: 2021-2023
Quantitative Coverage
- Market Size
- Market Shares
- Market Forecasts
- Market Growth Rates
- Units Sold
- Average Selling Prices
- Procedure Numbers
Qualitative Coverage
- COVID-19 Impact
- Market Growth Trends
- Market Limiters
- Competitive Analysis & SWOT for Top Competitors
- Mergers & Acquisitions
- Company Profiles
- Product Portfolios
- FDA Recalls
- Disruptive Technologies
- Disease Overviews
Data Sources
- Primary Interviews with Industry Leaders
- Government Physician Data
- Regulatory Data
- Hospital Private Data
- Import & Export Data
- iData Research Internal Database
TABLE OF CONTENT
- 4.1 Executive Summary
- 4.1.1 Global Orthopedic Bone Graft Substitute Market Overview
- 4.1.2 Competitive Analysis
- 4.1.3 Regions Included
- 4.2 Introduction
- 4.3 Procedure Numbers
- 4.3.1 Total Orthopedic Bone Grafting Procedures
- 4.3.2 Allograft Procedures
- 4.3.3 Demineralized Bone Matrix Procedures
- 4.3.4 Synthetic Procedures
- 4.4 Market Overview
- 4.4.1 By Segment
- 4.4.2 By Region
- 4.5 Market Analysis and Forecast
- 4.5.1 Total Orthopedic Bone Graft Substitute Market
- 4.5.2 Allograft Bone Graft Substitute Market
- 4.5.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
- 4.5.4 Synthetic Bone Graft Substitute Market
- 4.5.4.1 Synthetic Bone Graft Substitute Market by Generation Type
- 4.6 Unit Analysis
- 4.6.1 Allograft Bone Graft Substitute Unit Analysis
- 4.6.1.1 Allograft Bone Graft Substitute Units Sold by Indication
- 4.6.1.1.1 Spine Allograft Bone Graft Substitute Units Sold
- 4.6.1.1.2 Trauma Allograft Bone Graft Substitute Units Sold
- 4.6.1.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold
- 4.6.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Unit Analysis
- 4.6.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication
- 4.6.2.1.1 Spine Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
- 4.6.2.1.2 Trauma Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
- 4.6.2.1.3 Large Joint Reconstruction Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
- 4.6.3 Synthetic Bone Graft Substitute Unit Analysis
- 4.6.3.1 Synthetic Bone Graft Substitute Units Sold by Indication
- 4.6.3.1.1 Spine Synthetic Bone Graft Substitute Units Sold
- 4.6.3.1.2 Trauma Synthetic Bone Graft Substitute Units Sold
- 4.6.3.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold
- 4.7 Drivers and Limiters
- 4.7.1 Market Drivers
- 4.7.2 Market Limiters
- 4.8 Competitive Market Share Analysis